Aim: There are many people with type 2 Diabetes Mellitus (T2DM) worldwide. Rouxen-
Y Gastric Bypass (RYGB) is an effective surgery for treating T2DM with beneficial effects on
β cell metabolism. However, the mechanism of how RYGB affects the pancreas, is not clear. We
focused on metabolic changes in the pancreas of rats following RYGBand to investigate complex
postoperative pancreatic metabolic reprogramming and to understand how RYGB improves islet
Methods: We performed RYGBonstreptozotocin-induced male T2DM rats. Then we measured indicators
such as weight, fasting GLU, etc. After 10 weeks, pancreatic tissues were removed to identify
and quantify differentially expressed proteins. Furthermore, functional analysis of these proteins
and their associated pathways was conducted by bioinformatics methods.
Results: After surgery, 451 differentially expressed proteins associated with the mechanism
ofRYGB were identified. Protein levels of regenerating islet-derived protein 3 (Reg3A), cell division
cycle-associated protein 2 (CDCA2), and ADP-ribosylation factor 1 (Arf1) varied greatly, and
Arf1 may be a point target in diabetes.
Conclusion: This research shows that RYGB could treat T2DM through changes in the pancreatic
proteins. It will give some new insight into the molecular mechanism behind the effect of RYGB.